Device user fee legislation
This article was originally published in The Gray Sheet
Executive SummaryShould be delayed until effectiveness of existing drug user fee legislation can be assessed, Robert Britain, vice president of the National Electrical Manufacturers Association's diagnostic imaging and therapy systems division said at an April 1 hearing of the House Appropriations agriculture subcommittee. Testifying on FDA appropriations for fiscal 1994, Britain said that the Prescription Drug User Fee Act of 1992 "should be given a chance to work before additional discussions regarding the assessment of user fees from the medical device industry are initiated".
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.